Diabetes drug: Sanofi gets marketing authorization from CDSCO for Soliqua

Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.;

Published On 2023-03-28 09:44 GMT | Update On 2023-03-28 09:44 GMT

Mumbai: Sanofi (India) has announced that it has received marketing authorization for its diabetes drug Soliqua (in pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).

Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.

Cyrus Aibara, Head – Diabetes Business Unit, Sanofi (India) said, “With approximately 74 million Indians* (between the ages of 20-79 years) living with diabetes, healthcare professionals need more treatment options to customize diabetes care for them. Soliqua is the latest addition to our comprehensive diabetes portfolio (OADs and insulins) indicated for obese people who are living with insufficiently controlled diabetes. It will allow physicians to provide more tailored solutions for better diabetes management.”

Dr. Shalini Menon, Country Medical Lead, Sanofi (India) said, “Concerns about hypoglycemia and weight gain are known barriers when advancing diabetes treatments, more so when intensifying to a complex insulin regime. The global Solimix study** that included Indian patients, demonstrated that once daily Soliqua provides with weight benefit and less hypoglycaemia when compared with twice daily premixed insulin – thereby becoming a valuable option for endocrinologists.”

Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

Sanofi India Limited is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Today, it employs more than 3,000 employees across India.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Diabetes drug: Sanofi gets marketing authorization from CDSCO for Soliqua

Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.;

Similar News

Lupin bags USFDA approval for Multiple myeloma treatment

Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

India ranks among top global contributors in adverse event reporting: DCGI

Marketers Linked to Defaulting Pharma Units Under DCGI Lens

Intas Pharma Secures CDSCO Panel Approval for Post-Marketing Study of Tacrolimus Enema

Health Authorities Crack Down on OTC Sale of Antibiotics, NRx Drugs in Visakhapatnam

Merck gets USFDA Breakthrough Therapy Designation for Raludotatug deruxtecan for Platinum-Resistant Ovarian Cancer